* 香港富豪李嘉诚家族旗下从事葡萄园出租与癌症疫苗研发的长江生命科技0775.HK周五早盘低开1.9%，随后跌幅扩大至7.4%。
* 该公司此前公告称，预期2024年录得1.266亿港元股东应占亏损，对比2023年股东应占溢利为1,730万港元，乃归因于公司决意增加研发投资，以及葡萄园组合的公平值下降。
* 长江生命科技今年迄今涨24.4%，同期恒生指数.HSI上扬20.5%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌1.7%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 林高丽)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.